{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=73",
    "query": {
      "intervention": "Formulation #1",
      "page": 73
    },
    "page_size": 10
  },
  "pagination": {
    "page": 73,
    "page_size": 10,
    "total_count": 1760,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=74&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=72&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T08:02:01.638Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03931408",
      "title": "Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurogenic Bladder",
        "Spinal Cord Injuries"
      ],
      "interventions": [
        {
          "name": "Gentamicin Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo instillation (saline alone)",
          "type": "OTHER"
        },
        {
          "name": "No instillation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-02-19",
      "completion_date": "2020-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03931408"
    },
    {
      "nct_id": "NCT02648438",
      "title": "A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "AZD7594 Solution for infusion (150 μg intravenous formulation)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Oral suspension (1200 μg oral formulation)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Pressurized inhalation suspension (400 μg) by pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2016-01-12",
      "completion_date": "2016-06-01",
      "has_results": true,
      "last_update_posted_date": "2017-06-15",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02648438"
    },
    {
      "nct_id": "NCT07222878",
      "title": "Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy",
        "Alzheimer Disease",
        "Epilepsy Intractable"
      ],
      "interventions": [
        {
          "name": "NPT 2042 (Reference formula/Formulation 1)",
          "type": "DRUG"
        },
        {
          "name": "NPT 2042 (Test formula/Formulation 2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroPro Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2025-09-29",
      "completion_date": "2025-11-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222878"
    },
    {
      "nct_id": "NCT00600535",
      "title": "A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Neoplasms"
      ],
      "interventions": [
        {
          "name": "Stage 1 Group 1: abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 Group 2: abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Stage 2: abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Stage 3: abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Stage 3: glucocorticoid",
          "type": "DRUG"
        },
        {
          "name": "Stage 4: abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Stage 4: glucocorticoid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cougar Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2007-07",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2013-04-17",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600535"
    },
    {
      "nct_id": "NCT04411225",
      "title": "Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Psychosis"
      ],
      "interventions": [
        {
          "name": "Cannabidiol oral solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "16 Years to 30 Years"
      },
      "enrollment_count": 120,
      "start_date": "2022-06-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • San Diego, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04411225"
    },
    {
      "nct_id": "NCT07080385",
      "title": "Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Autosomal Dominant Hypocalcemia Type 1 (ADH1)"
      ],
      "interventions": [
        {
          "name": "Encaleret",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calcilytix Therapeutics, Inc., a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 28,
      "start_date": "2026-01-30",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07080385"
    },
    {
      "nct_id": "NCT06337643",
      "title": "A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumococcal Vaccine"
      ],
      "interventions": [
        {
          "name": "MVX01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVX01 Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Matrivax Research and Development Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 75,
      "start_date": "2023-03-07",
      "completion_date": "2024-04-16",
      "has_results": false,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 2,
      "location_summary": "Savannah, Georgia • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06337643"
    },
    {
      "nct_id": "NCT05818943",
      "title": "Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "GRIN-related Disorders"
      ],
      "interventions": [
        {
          "name": "Radiprodil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GRIN Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Months to 12 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-03-07",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • New York, New York",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05818943"
    },
    {
      "nct_id": "NCT07316608",
      "title": "A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X STP",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin Dose 1 STP",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin Dose 2 STP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2026-03-16",
      "completion_date": "2026-06-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07316608"
    },
    {
      "nct_id": "NCT00506285",
      "title": "Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Methylphenidate Transdermal System (MTS)",
          "type": "DRUG"
        },
        {
          "name": "placebo patch",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 92,
      "start_date": "2007-06",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2015-01-16",
      "last_synced_at": "2026-11-09T08:02:01.638Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506285"
    }
  ]
}